Department of General Surgery, First People's Hospital of Shanghai Jiaotong University, Hongkou District, Room 314, Building 9, No. 85 Wujing Road, Shanghai, China.
J Cancer Res Clin Oncol. 2010 Aug;136(8):1283-92. doi: 10.1007/s00432-010-0779-x. Epub 2010 Feb 16.
CD44v6 contributes to apoptosis resistance and metastasis via upregulated activity of the PI3K/AKT pathway. The purpose of this study was to investigate the expression patterns and predictive value of phosphorylated AKT (pAKT) and CD44v6 in breast cancer tissues.
Expression of pAkt and CD44v6 protein was detected using immunohistochemistry in breast cancer tissues and lymph node tissues in 98 patients. The correlation between the expression of pAkt, CD44v6 and other disease-related characteristics was investigated. The prognostic value of pAKT and CD44v6 overexpression for overall survival (OS) and disease free survival (DFS) was determined.
37 cases (37.8%) were observed as positive for pAkt expression, and 38 cases (38.8%) for CD44V6 overexpression. Staining was positive for pAKT in 20 of 38 (52.6%) CD44v6(+) and 17 of 60 (28.3%) CD44v6(-) (P = 0.016). A progressively increased trend of CD44v6 overexpression was observed from node(-) primary breast cancer tissues to node(+) primary cancer tissues to node(+) lymph tissues (P = 0.000). In univariate analysis lymph node status, pAKT and CD44V6 were significantly associated with a decreased OS and DFS. Multivariate analysis revealed that CD44v6 status was associated with a reduced OS (P = 0.003), and pAKT and CD44v6 with a shorter DFS (P = 0.012 and 0.016, respectively).
Our data suggested that there had an intensive relationship between pAKT and CD44v6 expression in breast cancer tissues. The overexpression of CD44v6 was an independent prognostic marker for predicting OS and DFS of breast cancer patients.
CD44v6 通过上调 PI3K/AKT 通路的活性促进细胞凋亡抵抗和转移。本研究旨在探讨磷酸化 AKT（pAKT）和 CD44v6 在乳腺癌组织中的表达模式及其预测价值。
采用免疫组织化学法检测 98 例乳腺癌组织及淋巴结组织中 pAkt 和 CD44v6 蛋白的表达情况，分析 pAkt、CD44v6 表达与其他疾病相关特征的相关性，判断 pAKT 和 CD44v6 过表达对总生存（OS）和无病生存（DFS）的预后价值。
pAkt 阳性表达 37 例（37.8%），CD44v6 过表达 38 例（38.8%）。38 例 CD44v6（+）中有 20 例（52.6%）pAKT 染色阳性，60 例 CD44v6（-）中有 17 例（28.3%）pAKT 染色阳性（P = 0.016）。从淋巴结阴性原发性乳腺癌组织到淋巴结阳性原发性乳腺癌组织再到淋巴结阳性淋巴结组织，CD44v6 过表达呈逐渐增加趋势（P = 0.000）。单因素分析显示，淋巴结状态、pAKT 和 CD44v6 与 OS 和 DFS 降低显著相关。多因素分析显示，CD44v6 状态与 OS 降低相关（P = 0.003），pAKT 和 CD44v6 与 DFS 缩短相关（P = 0.012 和 0.016）。
本研究数据表明，乳腺癌组织中 pAKT 与 CD44v6 表达之间存在密切关系。CD44v6 过表达是预测乳腺癌患者 OS 和 DFS 的独立预后标志物。
